$6.00
−4.15%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.16
From 52W high−98.60%
Volume8243.00
Market cap$3.04M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$6.16
From 52W high
−98.60%
Volume
8243.00
Market cap
$3.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.3x
P/E (TTM)
—
RSI (14)
75.5
MomentumView details →
1D Return
−4.15%
YTD Return
−66.68%
SummaryUpdated Jul 1, 2026
Clearmind Medicine Inc. (NASDAQ:CMND) is a pre-clinical stage biotechnology company founded in 2017 and based in Vancouver, Canada. The company went public in November 2022 and focuses on developing novel psychedelic-based medicines to treat underserved mental health conditions. Originally incorporated as Cyntar Ventures Inc., the company changed its name to Clearmind Medicine Inc. in March 2021 to reflect its specialized focus on psychedelic therapeutics. As a pre-clinical company, Clearmind has not yet generated revenue and remains in the early stages of drug development.
Similar companies
Latest newsMore news →
Clearmind Medicine announced that a patent application covering 3-MMC-based treatment of dyskinesia, including compositions combining 3-MMC with palmitoylethanolamide, was published in Japan.12d agoClearmind Medicine Inc. submitted recommendations to the U.S. Food and Drug Administration on regulatory pathways for psychedelic therapies and non-hallucinogenic neuroplastogens for alcohol use disorder.13d agoNeuroThera Labs highlighted the expansion of its U.S. patent portfolio through its ongoing collaboration with Clearmind Medicine, covering proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications.27d ago